Zinostatin and doxorubicin. A combination phase I study

Area of Science:

• Oncology
• Pharmacology
• Hepatocellular Carcinoma Research

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• Zinostatin and doxorubicin demonstrated promising single-agent activity in HCC.
• Combination therapy is explored to enhance treatment efficacy for advanced HCC.

Purpose of the Study:

• To evaluate the safety and tolerability of combined zinostatin and doxorubicin in HCC patients.
• To determine the maximum tolerated dose (MTD) for this combination regimen.
• To identify dose-limiting toxicities associated with the combination therapy.

Main Methods:

• Phase I clinical trial design.
• Fixed dose of zinostatin (2250 units/M2) administered over 5 consecutive days every 6 weeks.
• Doxorubicin dose (starting at 45 mg/m2) escalated/de-escalated by 33% based on tolerability.
• Monitoring for myelosuppression, cardiac function, and renal toxicity.

Main Results:

• Unpredictable, severe, and prolonged cumulative myelosuppression was a major dose-limiting toxicity.
• Three patients experienced congestive heart failure at cumulative doxorubicin doses of 195-270 mg/m2.
• Two patients exhibited potential drug-related nephrotoxicity.

Conclusions:

• The combination of zinostatin and doxorubicin presents significant toxicity challenges in HCC treatment.
• Severe myelosuppression and cardiotoxicity limit the tolerability of this regimen.
• Further combination studies with zinostatin are not recommended until its pharmacogenetic variability is understood.